Most Popular Stories
- Hospitals lose reimbursement for 'unnecessary' ER visits
- Healthcare jobs will grow the fastest of all industries
- Online tools, social media ease clinical recruiting, research
- Hospital exec arrested in $116M Medicare scheme
- Patient satisfaction equal for physician, hospitalist care
- New Hospital Compare data shows disparity in blood infection rates
Featured Jobs
-
Epic Ambulatory Beacon Consultant
Meditology Services - NC -
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA
Events
- Medicare Risk Adjusted Revenue and Plan Payments
April 12 - 13, 2012 — Baltimore, MD - ICD-10 Reality Check - Breakfast Panel at HiMSS 2012!
February 22, 2012 - AHIP's Institute 2012
June 20-22 — Salt Lake City, UT - CIO Healthcare Summit
March 11-14 — Scottsdale, AZ
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
Few drugs being developed for pregnant women
While the subject isn't discussed much, it's an open secret that there are few drugs that serve the health needs of the 4 million American women who give birth each year. In fact, in many cases doctors can save mothers and babies with critical pregnancy-related conditions only by delivering babies early, which creates its own set of health problems. Worldwide, scientists are actively developing on 17 medicines for material health, less than 3 percent of the 660 drugs being developed for heart disease and half as many as for Lou Gehrig's disease, which affects only 5,600 patients per year.
Meanwhile, researchers seldom tests drugs for common conditions, such as depression on pregnant women. And no new classes of drugs have been approved for conditions of pregnancy, such as pre-term labor or a liver problem known as cholestatis, leaving OBs with decades-old medicines--or forcing them to prescribe off-label drugs at a time when women and their babies are especially vulnerable, according to Nicholas Fisk, an obstetrician-gynecologist and director of the University of Queensland Centre for Clinical Research in Australia.
However, such slow development of maternal drugs is unlikely to change in the near term, given the risks of testing drugs on pregnant women, observers note. No one (especially drug makers) has forgotten the lessons of thalidomide, the morning sickness drug that caused severe limb deformities in babies, or DES, which caused cancer in daughters of women who took it. Pharmas also bear in mind the controversy over morning sickness drug Bendectin which, despite scientific tests finding no increased risk of birth defects, was blamed for such defects by some women. Merrell Dow Pharmaceuticals stopped making the drug. (Not long after, the number of pregnant women hospitalized for nausea and vomiting increased substantially.)
To learn more about this issue:
- read this USA Today article
Related Stories
- Conflicts of interest remain as docs receive $760M from drug makers
- Heart issue hospitalizations drop among Medicare patients
- CMS to fund $100M in Medicaid grants to encourage healthy living
- Colorado teaching hospitals overhaul conflict of interest rules
- Big drug companies wield too much influence over doctors
- Study: Attitudes over doctor-industry ties not as evolved as we think
- SPOTLIGHT: Relationships between docs, drug companies also a problem in India
- Price hikes could raise $10 billion in additional income for pharmas
- Reform bill would require pharma disclosures of CME funding
- Pharmas settle $124M Medicaid fraud suit; Legislators fight for 'critical access' funding for rural hospitals;
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
